628
Participants
Start Date
December 31, 2004
Primary Completion Date
September 30, 2007
Study Completion Date
September 30, 2007
Levitra (Vardenafil, BAY38-9456)
9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
Levitra (Vardenafil, BAY38-9456)
9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
Placebo
9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
Bruxelles - Brussel
Bruxelles - Brussel
Johannesburg
Moelv
Edegem
Leuven
Bern
Tønsberg
Pietermaritzburg
Hasselt
Liège
Salzburg
Cape Town
Cape Town
Graz
Poughkeepsie
Genova
Lancaster
Milan
Milan
Hamburg
Madrid
Málaga
Nîmes
Tampere
Trieste
Vigo
Braunschweig
Jackson
Dortmund
Herne
Valencia
Valencia
Jeffersonville
Osnabrück
Florence
Des Moines
Leverkusen
Lille
Offenbach
Mannheim
Saint-Genis-Laval
Lyon
Bari
Tübingen
Oklahoma City
Napoli
München
München
Carpentras
Oulu
Weiden
Laguna Hills
Spokane
Cincinnati
Columbus
Providence
Calgary
Edmonton
Barrie
London
Oakville
Toronto
Chicoutimi
Fleurimont
St. John's
Victoria
Oulu
Leiden
Nijmegen
Rotterdam
Pretoria
Barcelona
Barcelona
Gothenburg
Gothenburg
Halmstad
Lund
Skövde
Västerås
Bath
Bristol
Slough
London
Manchester
Taunton
Lead Sponsor
Bayer
INDUSTRY